Fundz
Following Nika Pharmaceuticals?

Get the free weekly contract digest

The latest new contracts, like Nika Pharmaceuticals’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Nika Pharmaceuticals, Inc. Signed Distribution Agreement with I.Conntact-Connect Limited for Nigeria

Jul 18, 2024•almost 2 years ago

Contract Type

agreement

BiotechnologyHealth CarePharmaceutical

Description

Nika Pharmaceuticals, Inc. announced the signing of a distribution agreement with I.Conntact-Connect Limited for the Republic of Nigeria. The agreement will allow NIKA to have a strong partner in a key market of 229 million people for the distribution of ITV-1, which could result in €7.9 billion revenue and help the battle against a national HIV epidemic.

Company Information

Company

Nika Pharmaceuticals

About

Nika Pharmaceuticals, Inc. (NIKA) is a pharmaceutical company, specializing in the treatment of HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, Diabetes, and all diseases, for which strengthened cell immunity is of vital importance. NIKA's intellectual property includes six drugs in injection form – two of which have successfully undergone clinical trials with good treatment results – four drugs in tablet form, and eleven dietary supplements. NIKA’s goal is to not only achieve corporate profits, but to provide better and easier access to life-saving medicinal drugs and useful dietary supplements.

Predictive Intelligence
Strategic

ML-powered predictions for Nika Pharmaceuticals's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.